Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label …

PR Galle, RS Finn, S Qin, M Ikeda, AX Zhu… - The Lancet …, 2021 - thelancet.com
Background Understanding patients' experience of cancer treatment is important. We aimed
to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus …
被引用次数：249 相关文章

[引用][C] Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an …

P Galle, R Finn, S Qin, M Ikeda, A Zhu, TY Kim… - Lancet …, 2021 - hal.science
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in
patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label …

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label …

PR Galle, RS Finn, S Qin, M Ikeda, AX Zhu… - The Lancet …, 2021 - europepmc.org
Background Understanding patients' experience of cancer treatment is important. We aimed
to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus …

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label …

PR Galle, RS Finn, SK Qin, M Ikeda… - LANCET …, 2021 - scholarworks.bwise.kr
Background Understanding patients' experience of cancer treatment is important. We aimed
to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus …

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label …

PR Galle, RS Finn, S Qin, M Ikeda, AX Zhu… - The Lancet …, 2021 - thelancet.com
Background Understanding patients' experience of cancer treatment is important. We aimed
to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus …

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label …

PR Galle, RS Finn, S Qin, M Ikeda… - The Lancet …, 2021 - snucm.elsevierpure.com
Background: Understanding patients' experience of cancer treatment is important. We aimed
to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus …

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label …

PR Galle, RS Finn, S Qin, M Ikeda, AX Zhu, TY Kim… - The Lancet …, 2021 - Elsevier
Background Understanding patients' experience of cancer treatment is important. We aimed
to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus …

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label …

PR Galle, RS Finn, S Qin, M Ikeda… - The Lancet …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Understanding patients' experience of cancer treatment is important. We aimed
to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus …

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label …

PR Galle, RS Finn, S Qin, M Ikeda… - The lancet …, 2021 - mdanderson.elsevierpure.com
Background: Understanding patients' experience of cancer treatment is important. We aimed
to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus …

[引用][C] Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an …

PR Galle, RS Finn, S Qin, M Ikeda, AX Zhu, TY Kim… - The Lancet …, 2021 - cir.nii.ac.jp
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients
with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase …